Key Takeaways
- Petrelintide demonstrated 10.7% weight reduction at the 42-week mark in Phase 2 testing — falling short of the 12–15% analyst consensus
- Leading financial institutions including JPMorgan, Jefferies, UBS, and Barclays expressed concern over the underwhelming results
- Cantor Fitzgerald revised its rating to Neutral, moving down from Overweight
- Competing therapies from Eli Lilly (eloralintide) and Novo Nordisk (cagrilintide) demonstrate superior performance profiles
- Absence of dose-dependent response between highest dosage groups creates uncertainty about Phase 3 improvement potential
Shares of Zealand Pharma (ZEAL) tumbled over 32% on Friday following the release of Phase 2 clinical trial results for petrelintide, its experimental obesity treatment, which failed to meet Wall Street’s performance expectations.
The ZUPREME-1 clinical study, conducted in collaboration with Roche, evaluated petrelintide in adults classified as overweight or obese who did not have type 2 diabetes. Participants receiving the maximum dosage achieved an average body weight reduction of 10.7% by week 42 using an efficacy estimand analysis.
While the study successfully achieved its primary endpoint by demonstrating statistically significant weight reductions at the 28-week checkpoint across all dosage levels compared to placebo, the topline figure failed to satisfy market expectations.
Wall Street analysts had projected weight loss results in the 12% to 15% range to demonstrate competitive viability. The actual 10.7% outcome fell considerably below this benchmark.
JPMorgan analyst Sophia Graeff Buhl Nielsen characterized the outcome as “falls slightly short of expectations,” though she noted the findings still “leaves scope for an attractive mid-teens weight loss profile to be achieved in Phase 3,” particularly if future enrollment includes more female participants — who demonstrated enhanced treatment responses.
Jefferies identified the results as likely disappointing, noting they missed both its internal projection of 13% to 15% and buy-side expectations exceeding 15%. Analyst Lucy Codrington described petrelintide as delivering “Wegovy-like efficacy, but with placebo-like tolerability,” characterizing it as “viable” though probably “2nd-best to LLY’s elora for now.”
The drug demonstrated strong performance in the tolerability category. The maximum-dose cohort reported zero vomiting incidents and minimal gastrointestinal adverse effects — what Codrington termed “placebo-like.” While this represents a genuine advantage, it proved insufficient to offset efficacy concerns.
Cantor Fitzgerald Revises Rating to Neutral
Cantor Fitzgerald downgraded Zealand Pharma from Overweight to Neutral, citing insufficient differentiation from competitors. The firm noted petrelintide’s placebo-adjusted weight reduction of approximately 9% at the 42-week timepoint mirrors Novo Nordisk’s cagrilintide performance — and significantly trails Eli Lilly’s eloralintide.
Cantor highlighted the absence of dose-response relationships as problematic, indicating no clear pathway for enhanced weight loss in subsequent trials. The firm now projects petrelintide will achieve weight reductions in the low-to-mid teens range, comparable to cagrilintide.
Given that Eli Lilly has already advanced eloralintide into Phase 3 trials and Novo Nordisk has similarly progressed cagrilintide monotherapy to Phase 3, Cantor suggested petrelintide faces potential launch as a third-entrant with minimal differentiation. This positioning presents substantial commercial challenges.
Future Considerations
UBS observed the trial results arrived “clearly at the lower end of expectations” and questioned petrelintide’s prospects as a standalone monotherapy. Nevertheless, the firm identified a combination strategy — pairing petrelintide with a reduced dose of Roche’s CT-388 — as a “still viable option,” citing the compound’s favorable tolerability characteristics.
Minimal differentiation emerged between the highest dosage cohorts, with weight loss spanning 10.2% to 10.7%. JPMorgan suggested this pattern may indicate limited additional benefit from dose escalation.
Comprehensive trial data is scheduled for presentation at a scientific conference during 2026.
The stock was last trading at $38.22, representing approximately 51% below its 52-week peak of $112.63.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
